紫杉醇联合卡铂同步放疗对老年非小细胞肺癌患者肿瘤标志物的影响

打开文本图片集

The Effect of Paclitaxel Combined with Carboplatin Synchronous Radiotherapy on Tumor Markers inElderly Patients with Non-smallCell Lung Cancer/LEI Yugang，HU Honglin.//Medical Innovationof China，2025，22（24）：125-129

[Abstract] Objective： To analyze the effects of Paclitaxel combined with Carboplatin synchronous radiotherapy on tumor markers in elderly patients with non-smallcell lung cancer （NSCLC）.Method： Seventy elderlyNSCLC patients admited to Sichuan Provincial People's Hospital from January 2O21 to January 2024 were selected and divided into an observation group （ n =35，treatedwithPaclitaxelcombinedwithCarboplatin synchronous radiotherapy） and a control group （ n =35，treated with Paclitaxel combined with Cisplatin synchronous radiotherapy）according to the random lottery method.The clinical outcomes of the two groups were compared. Result： The total effective rate of the observation group was 94.29 % ，which was higher than 77.14% of the control group，the incidence of leukopenia （2.86% ），nauseaand vomiting （11.43 % ），alopecia （14.29 % ），thrombocytopenia （20 （2.86%） ， and muscle and joint pain （2.86% ） in the observation group were lower than those in the control group 20.00% 34.29% 37.14% 20.00% 22.86% ），thedifferenceswere statistically significant （ P <0.05）. There were no

significant differences in the levelsofcytokeratin19 fragmentantigen （Cyfra21-1），carcinoembryonic antigen（CEA）， and squamous cell carcinoma antigen （SCC-Ag） between the two groups before treatment （ P>0.05 ），after treatment， the Cyfra 21-1 of the observation group was （20.01±1.76 ） μg/L ， CEA was 18.25±2.18 ） ng/mL，and SCC-Ag was （204号 （8.51±2.30）ng/L ，whichwerelower than （25.94±2.10 ） μg/L ， （22.23±2.24）ng/mL ，and （10.34±2.26）ng/L of the control group，the differences were statistically significant （P<0.05） .Conclusion：Inthe clinical treatment of elderly NSCLC patients，the useof Paclitaxel combined with Carboplatin synchronous radiotherapy has a relativelydefinite effect，with guaranteed effectiveness and safety，and can reduce tumor marker levels.

[Keywords]PaclitaxelCarboplatinSynchronous radiotherapyNon-smallcelungcancerTumor markers First-author'saddress： Chengdu Universityof Traditional Chinese Medicine， Chengdu 61oo75， China doi： 10.3969/j.issn.1674-4985.2025.24.029

肺癌是临床常见的恶性肿瘤，其中非小细胞肺癌（NSCLC）的占比约为 80% ，NSCLC发病后的初期阶段，通常并未表现出特异症状，导致疾病错过最佳的诊断和治疗时机[1-2]。（剩余5161字）